Peer-reviewed veterinary case report
Chemotherapy options for dogs with T-cell or hypercalcemic lymphoma
By Angelo, G et al.·Published in The Journal of small animal practice·2019·Veterinary Specialty Care·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Comparison of combination l-asparaginase plus CHOP or modified MOPP treatment protocols in dogs with multi-centric T-cell or hypercalcaemic lymphoma.
- Species:
- dog
Plain-English summary
A group of dogs diagnosed with high-grade T-cell lymphoma were treated with two different chemotherapy protocols to see which one worked better. One group received a combination of cyclophosphamide, doxorubicin, vincristine, and prednisone, while the other group was treated with a modified version of mechlorethamine, vincristine, prednisone, and procarbazine. The dogs treated with the first protocol had a median progression-free survival of 133 days, compared to 97 days for those on the second protocol. Notably, golden retrievers showed even better results with the first treatment, lasting an average of 154 days.
People also search for: dog lymphoma treatment options · golden retriever cancer survival rates · chemotherapy for dogs with lymphoma
Abstract
OBJECTIVES: To compare the progression-free survival of dogs with high-grade T-cell lymphoma treated with either a cyclophosphamide, doxorubicin, vincristine and prednisone-based or a modified mechlorethamine, vincristine, prednisone and procarbazine chemotherapy protocol. MATERIALS AND METHODS: In this retrospective study, cases were selected based on histologic or cytologic diagnosis of lymphoma, T-cell phenotype, hypercalcaemia, or both, and no previous chemotherapy for lymphoma. Treatment was not randomly allocated. RESULTS: Seventy-three dogs were included in this study: 50 in the cyclophosphamide, doxorubicin, vincristine and prednisone group and 23 in the mechlorethamine, vincristine, prednisone and procarbazine group. The median progression-free survival was 133 days for dogs in the cyclophosphamide, doxorubicin, vincristine and prednisone group and 97 days for dogs in the mechlorethamine, vincristine, prednisone and procarbazine group. When golden retrievers (n = 16) were evaluated -separately, progression-free survival was longer in the cyclophosphamide, doxorubicin, vincristine and prednisone versus mechlorethamine, vincristine, prednisone and procarbazine treatment group (median PFS 154 days versus 70.5 days, respectively). CLINICAL SIGNIFICANCE: The progression-free survival time for dogs with multi-centric T-cell lymphoma treated with a modified mechlorethamine, vincristine, prednisone and procarbazine protocol was similar to that of dogs treated with cyclophosphamide, doxorubicin, vincristine and prednisone. Further studies, including those evaluating golden retrievers separately, are needed to confirm these findings.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30790291/